Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient did not take last dose of Vivotif; Case reference number US-BN-2025-001706 is a spontaneous case initially received from other health professional via Bavarian Nordic Safety (reference number: CASE-000359) on 20-Oct-2025 and concerns a 27-year-old female patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown, expiration date: unknown), at an unknown dose, route of administration for an unknown indication. On an unspecified date, an unknown amount of time from the first dose, the patient took the second dose of Vivotif batch number: unknown, expiration date: unknown), at an unknown dose, route of administration. On an unspecified date, an unknown amount of time from the first dose, the patient took the third dose of Vivotif batch number: unknown, expiration date: unknown), at an unknown dose, route of administration. On an unspecified date, an unknown amount of time from the first dose, the patient did not take the fourth dose of Vivotif (batch number: unknown, expiration date: unknown) (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown whether the patient experienced any adverse event due to Vivotif. No further information's were provided.; Reporter's Comments: A 27-year-old female patient did not take the fourth dose of Vivotif, which is considered as missed dose. It was unknown whether the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 27-year-old female patient did not take the fourth dose of Vivotif, which is considered as missed dose. It was unknown whether the patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE.